CLAIMS

What is claimed is:

1. A pharmaceutical composition, comprising:

two chemically linked anti-viral agents wherein the first anti-viral agent is the ribose alcohol active metabolite of remdesivir, and the second anti-viral agent is hydroxychloroquine or dexamethasone, wherein the two chemically linked anti-viral agents are combined with a carrier suitable for respiratory administration to a patient via vaporization wherein heat of vaporization is capable of decoupling the two chemically linked anti-viral agents, and wherein the chemical link between anti-viral comprises at least one carbamate or carbonate group.

2. Use of two chemically linked anti-viral agents in the manufacture of a pharmaceutical composition for treating a viral disease selected from the group consisting of SARS, MERS, and SARS-CoV-2, wherein the first anti-viral agent is the ribose alcohol active metabolite of remdesivir, and the second anti-viral agent is hydroxychloroquine or dexamethasone, and wherein the two chemically linked anti-viral agents are combined with a carrier suitable for respiratory administration to a patient via vaporization wherein the heat of vaporization is capable of decoupling the two chemically linked anti-viral agents, and wherein the chemical link between anti-viral agents comprises at least one carbamate or carbonate group.

3. The use of claim 2, wherein the pharmaceutical composition further comprises an anti-bacterial, anti-fungal, or anti-protozoal agent.